Identification of hit compounds with antischistosomal activity on in vitro generated juvenile worms in cell-free medium

Bibliographic Information
Authors: Vejzagić N.; Prodjinotho U.F.; El-Khafif N.; Huang R.; Simeonov A.; Spangenberg T.; da Costa C.P.
Journal: PLoS Neglected Tropical Diseases
Publisher: Public Library of Science
Publication Date: 25 May 2021
Volume / Issue: Volume 15 / Issue 5
Article No.: e0009432
ISSN: 19352727
DOI: 10.1371/journal.pntd.0009432
Scopus: View on Scopus
PubMed: 34033658
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Vejzagić N., Institute for Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Center for Global Health, TUM School of Medicine, Technische Universität München, Munich, Germany; Prodjinotho U.F., Institute for Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Center for Global Health, TUM School of Medicine, Technische Universität München, Munich, Germany; El-Khafif N., Theodor Bilharz Research Institute, Mahad Al Abhas Al Bahari, Warraq Al Arab, El Warraq, Giza Governorate, Egypt; Huang R., Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States; Simeonov A., Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States; Spangenberg T., Global Health Institute of Merck, Ares Trading S.A. (a subsidiary of Merck KGaA Darmstadt Germany), Eysins, Switzerland; da Costa C.P., Institute for Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Center for Global Health, TUM School of Medicine, Technische Universität München, Munich, Germany
Abstract
Background Anthelminthic treatment options against schistosomiasis are limited. The current treatment relies almost exclusively on a single drug, praziquantel (PZQ). As a consequence, the development of resistance to PZQ and limited activity of PZQ against earlier development stages are respectively a risk and a limitation to achieving the goals of the new WHO roadmap towards elimination. For the discovery of new chemical starting points, the in vitro drug screening on Schistosoma mansoni (S. mansoni) against newly transformed schistosomula (NTS) is still the most predominant approach. The use of only NTS in the initial screening limits sensitivity to potential new compounds which are predominantly active in later developmental stages. Using our recently described highly standardized, straightforward and reliable culture method that generates high rates of juvenile worms, we aimed to repurpose a subset of the NCATS Pharmaceutical Collection (340 compounds) to identify new hits with an in vitro worm culture assay. Methodology/Principal findings Cercariae were mechanically transformed into skin-stage (SkS) schistosomula and continuously cultured for 3-6 weeks to the liver stage (LiS). A commercial source of serum was identified, and decrease of NTS/well along with optimal drug testing conditions was established to test compounds on early and late LiS worms. The library was screened in 96-well format assays using praziquantel (PZQ) as a positive control. Primary screening allowed a 5.9% hit rate and generated two confirmed hits on adult worms; a prophylactic antianginal agent and an antihistaminic drug. Conclusion With this standardized and reliable in vitro assay, important S. mansoni developmental stages up to LiS worms can be generated and cultured over an extended period. When exposed to a subset of the National Center for Advancing Translational Sciences (NCATS) Pharmaceutical Collection, 3 compounds yielded a defined anti-schistosomal phenotype on juvenile worms. Translation of activity on perfused adult S. mansoni worms was achieved only for perhexiline (a prophylactic antianginal agent) and astemizole (an antihistaminic drug). © 2021, Public Library of Science. All rights reserved.
Keywords
Animals; Astemizole; Drug Evaluation, Preclinical; In Vitro Techniques; Perhexiline; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides; alverine; antiangina pectoris agent; antihistaminic agent; antineoplastic agent; antischistosomal agent; aprindine; berberine; bifemelane; dibenzepin; dilazep; dimethyl sulfoxide; fasoracetam; flupentixol; gallopamil; ifenprodil; nefopam; paraoxon; penicillin derivative; pentobarbital; pizotifen; praziquantel; sanguinarine; sertindole; spiperone; streptomycin; thioproperazine; animal cell; animal experiment; animal tissue; antiprotozoal activity; Article; Biomphalaria glabrata; body height; bright field microscopy; cell structure; cell viability; cercaria; cheminformatics; controlled study; drug screening; granulation tissue; in vitro study; integument; juvenile; lipophilicity; mitochondrion; nonhuman; oocyte maturation; parasite viability; parenchyma; phenotype; prothrombin time; quality control; scanning electron microscopy; schistosomiasis; schistosomulum; transmission electron microscopy; animal; drug effect; growth, development and aging; preclinical study; procedures
Citation Information
Scopus Citations: 3
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
